IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Collins who wrote (63)	11/11/1996 2:23:00 PM
From: Rudy Saucillo	of 305

Michael, I think that's a very respectable purchase price and certainly better than I did. IMUL recently released its qtrly report with no surprises that I could find. The settlement with HMRI, I believe, was in line with expectations. The next news may be announcement of the status of Allervax Cat - i.e., whether or not the FDA requires an additional trial. I believe that it is generally expected by investors that another trial will be required. However, we may still see a slight dip if this is the case but certainly no significant sell-off. Re other expected news, IMUL will likely announce the initiation of Phase I clinical trials for their MS therapy. Also, in their qtrly report, IMUL stated they will present pivital results from their ongoing Ragweed trial in first quarter '97. No surprise - this is the same schedule as last year's trial. Of course, the news that investors are waiting on is announcement of a new Allervax partnership for commercialization of Ragweed and Cat as well as development of their Allervax pipeline. This should come anywhere between now and end of first quarter '97. Happy investing! Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next